Euro-Sante :: Euro-Health

It would be a serious mistake not have an EU-wide regulatory framework for internet pharmacies. Not achieving one would be just more evidence of the politics that infects all discussions of cross-border healthcare to the detriment of the patient and health consumer. Illegal drugs, fake drugs, reimported drugs, counterfeit drugs, substandard drugs, legitimate drugs —… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

Recent research suggests that the European pharmaceutical industry is more productive than the US one. Euractive reports on this here: article-184974. A few things to consider. Light’s work is a reanalysis of existing data. His conclusions are based on using the head-office of the company discovering the drug as determining the country of origin. He… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

Annalee Saxenian, an astute observer and analyst of the regional advantage of Silicon Valley, observes in her book, The New Argonauts, that the Valley has gained as its home-grown entrepreneurs have built overseas businesses in China, India and elsewhere. She notes: “By promoting the development of local capabilities in Tel Aviv, Hsinchu, Shanghai, Bangalore, and… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

NICE is the health technology assessment [HTA] agency in England, the one upon which others in many countries are modelled. More generally, HTA is increasingly being used by governments for more than simple economic evaluation of medicines and devices, but is being used as a form of rationing of access to technologies (medicines or devices… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

Sweden is home to the Karolinska Institute, one of the most effective bio-medical institutions in the EU. The worst thing the EU could do would be to copy Sweden; they are exemplary. What should be left behind at the end of December is a commitment by member states to unleash the creativity in their research… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

The Swedish presidency has identified a number of health priorities. I’d like to reflect on the following: 1. patient mobility directive, 2. e-health cooperation, and 3. flu. Patient mobility adds cross-border health risk as people with diseases move around. Zoonoses, diseases caught from animals (and it is worth remembering that animals catch diseases from humans,… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

Considerable public funding goes into research. To the dismay, though, of many, European countries in the main are very poor at commercialising this research, and thus return of this public investment is often zero euros. Reasons lie in at least two places: EU member states (outside of the ‘anglo’ tradition) tend to ‘own’ their own… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante

The British have raised the issue that cross-border healthcare will only benefit the few: All EU citizens, not just the wealthy or well informed, must be able to benefit Baroness Howarth of Breckland, of the House of Lords’ EU Committee Is this fear or concern justified? The whole point of enabling European citizens to have… » read more

Tweet about this on TwitterShare on FacebookShare on Google+Share on LinkedIn

Posted by EuroSante